Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe

被引:294
作者
Mocroft, A
Kirk, O
Barton, SE
Dietrich, M
Proenca, R
Colebunders, R
Pradier, C
Monforte, AD
Ledergerber, B
Lundgren, JD
机构
[1] UCL, Royal Free & Univ Coll Med Sch, Royal Free Ctr HIV Med, London NW3 2PF, England
[2] Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat Sci, London, England
[3] Hvidovre Univ Hosp, EuroSIDA Coordinating Ctr, Copenhagen, Denmark
[4] Chelsea & Westminster Hosp, London, England
[5] Bernhard Nocht Inst Trop Med, Hamburg, Germany
[6] Hosp Curry Cabral, Lisbon, Portugal
[7] Inst Trop Med, B-2000 Antwerp, Belgium
[8] Hop Archet, Nice, France
[9] Osp L Sacco, Milan, Italy
[10] Univ Hosp, Zurich, Switzerland
关键词
anaemia; CD4; count; viral load; mortality;
D O I
10.1097/00002030-199905280-00010
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: To describe changes in haemoglobin over time and to determine the joint prognostic value of the current haemoglobin, CD4 lymphocyte count and viral load among patients from across Europe. Patients: The analysis included 6725 patients from EuroSIDA, an observational, prospective cohort of patients with HIV from across Europe. Methods: Normal haemoglobin was defined as haemoglobin greater than 14 g/dl for men and 12 g/dl for women; mild anaemia was 8-14 g/dl for men and 8-12 g/dl for women; severe anaemia was defined as less than 8 g/dl for both males and females. Linear regression techniques were used to estimate the annual change in haemoglobin; standard survival techniques were used to describe disease progression and risk of death. Results: At recruitment, to the study, 40.4% had normal levels of haemoglobin, 58.2% had mild anaemia and 1.4% had severe anaemia. At 12 months after recruitment, the proportion of patients estimated to have died was 3.1% [95% confidence interval (CI) 2.3-3.9] for patients without anaemia, 15.9% for patients with mild anaemia (95% CI 14.5-17.2) and 40.8% for patients with severe anaemia (95% CI 27.9-53.6; P < 0.0001). In a multivariate, time-updated Cox proportional hazards model, adjusted for demographic factors, AIDS status and each antiretroviral treatment as time-dependent covariates, a 1 g/dl decrease in the latest haemoglobin level increased the hazard of death by 57% [relative hazard (RH) 1.57; 95% CI 1.41-1.75; P < 0.0001], a 50% drop in the most recent CD4 lymphocyte count increased the hazard by 51% (RH 1.51; 95% CI 1.35-1.70; P < 0.0001) and a log increase in the latest viral load increased the hazard by 37% (RH 1.37; 95% CI 1.15-1.63; P = 0.0005). Conclusions: Severe anaemia occurred infrequently among these patients but was associated with a much faster rate of disease progression. Among patients with similar CD4 lymphocyte counts and viral load, the latest value of haemoglobin was a strong independent prognostic marker for death. (C) 1999 Lippincott Williams & Wilkins.
引用
收藏
页码:943 / 950
页数:8
相关论文
共 41 条
[1]  
[Anonymous], 1989, SAS STAT US GUID VER
[2]   PROGNOSTIC FACTORS IN HUMAN IMMUNODEFICIENCY VIRUS-POSITIVE PATIENTS WITH A CD4(+) LYMPHOCYTE COUNT LESS-THAN-50/MU-L [J].
APOLONIO, EG ;
HOOVER, DR ;
HE, YH ;
SAAH, AJ ;
LYTER, DW ;
DETELS, R ;
KASLOW, RA ;
PHAIR, JP .
JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (04) :829-836
[3]  
Berliner Nancy, 1995, P468
[4]  
[Anonymous], 1992, MMWR Recomm Rep, V41, P1
[5]  
CHYENE G, 1997, AIDS, V11, P209
[6]   Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection [J].
Coombs, RW ;
Welles, SL ;
Hooper, C ;
Reichelderfer, PS ;
DAquila, RT ;
Japour, AJ ;
Johnson, VA ;
Kuritzkes, DR ;
Richman, DD ;
Kwok, S ;
Todd, J ;
Jackson, JB ;
DeGruttola, V ;
Crumpacker, CS ;
Kahn, J .
JOURNAL OF INFECTIOUS DISEASES, 1996, 174 (04) :704-712
[7]  
Cox D. R., 1984, ANAL SURVIVAL DATA
[8]   Hematologic complications of human immunodeficiency virus infection and the acquired immunodeficiency syndrome [J].
Coyle, TE .
MEDICAL CLINICS OF NORTH AMERICA, 1997, 81 (02) :449-+
[9]   SURVIVAL EXPERIENCE AMONG PATIENTS WITH AIDS RECEIVING ZIDOVUDINE - FOLLOW-UP OF PATIENTS IN A COMPASSIONATE PLEA PROGRAM [J].
CREAGHKIRK, T ;
DOI, P ;
ANDREWS, E ;
NUSINOFFLEHRMAN, S ;
TILSON, H ;
HOTH, D ;
BARRY, DW .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1988, 260 (20) :3009-3015
[10]   RATE OF CD4 CELL DECLINE AND PREDICTION OF SURVIVAL IN ZIDOVUDINE-TREATED PATIENTS [J].
EASTERBROOK, PJ ;
EMAMI, J ;
GAZZARD, B .
AIDS, 1993, 7 (07) :959-967